Overview

Webcast ImageWebcast
MannKind at Morgan Stanley Healthcare Conference (Replay)
09/09/14 at 12:55 p.m. ET

MannKind Corporation (Nasdaq:MNKD) is a biopharmaceutical company that focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Our lead investigational product candidate, AFREZZA® , is an ultra rapid-acting insulin. AFREZZA is in late stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia.

Featured Links


Receive E-mail AlertsE-mail Alert Icon
Alerts are e-mailed to you whenever certain new company information is posted to this site.
Sign-up Now!
MNKD (Common Stock)
ExchangeNASDAQ GM (US Dollar)
Price$6.19
Change (%) Stock is Down 0.19 (2.98%)
Volume7,128,800
Data as of 09/16/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore Press Releases
DateTitle 
09/02/14MannKind Corporation to Present at Morgan Stanley Global Healthcare Conference
VALENCIA, Calif., Sept. 2, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD), focused on discovering, developing and commercializing therapeutic products for diabetes, announced today that it will present at The Morgan Stanley Global Healthcare Conference on Tuesday, September 9, 2014 at 12:55 PM (ET) at the Grand Hyatt Hotel in New York City. Interested parties can access a link to the live webcast of the presentations from the News & Events section of the Company's website at ht... 
Printer Friendly Version
08/11/14Sanofi and MannKind Announce Global Licensing Agreement for Afrezza® (insulin human) Rapid-Acting Inhaled Insulin
Paris and Valencia, Calif. - August 11, 2014 - Sanofi (EURONEXT: SAN and NYSE: SNY) and MannKind Corporation (Nasdaq: MNKD) announced today that they have entered into a worldwide exclusive licensing agreement for development and commercialization of Afrezza® (insulin human) Inhalation Powder, a new rapid-acting inhaled insulin therapy for adults with type 1 and type 2 diabetes. The companies plan to launch Afrezza in the United States in the first quarter of 2015. Under the collabo... 
Printer Friendly Version
08/11/14MannKind Corporation Reports 2014 Second Quarter Financial Results
VALENCIA, Calif., Aug. 11, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today reported financial results for the second quarter ended June 30, 2014. For the second quarter of 2014, total operating expenses were $69.8 million, compared to $41.6 million for the second quarter of 2013, an increase of $28.2 million, largely due to an increase in non-cash stock compensation expense of $30.5 million. In the second quarter of 2014, the settlement terms for certain performance-based a... 
Printer Friendly Version
08/05/14MannKind Corporation to Hold 2014 Second Quarter Financial Results Conference Call on August 11, 2014
VALENCIA, Calif., Aug. 5, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) will release its 2014 second quarter financial results on Monday, August 11, 2014 and its management will host a conference call to discuss the second quarter financial results and other Company developments at 5:00 PM (Eastern Time) on August 11, 2014. Presenting from the Company will be its Chairman and Chief Executive Officer, Alfred Mann, President and Chief Operating Officer, Hakan Edstrom, and Corpora... 
Printer Friendly Version
Quotes delayed at least 15 minutes. Market data provided by Interactive Data.

Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.



Print Page Print | E-mail Page E-mail Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts | IR Contacts IR Contacts | Financial Tear Sheet Tear Sheet